4E1RCat | CAS#328998-25-0

MedKoo Cat#: 530395 | Name: 4E1RCat

Description:

WARNING: This product is for research use only, not for human or veterinary use.

4E1RCat is an inhibitor of the eIF4F translation initiation complex that blocks eIF4E:eIF4G and eIF4E:4E-BP1 interactions.

Chemical Structure

4E1RCat

CAS#328998-25-0

Theoretical Analysis

MedKoo Cat#: 530395

Name: 4E1RCat

CAS#: 328998-25-0

Chemical Formula: C28H18N2O6

Exact Mass: 478.1165

Molecular Weight: 478.46

Elemental Analysis: C, 70.29; H, 3.79; N, 5.86; O, 20.06

Price and Availability

Size	Price	Availability
10mg	USD 150.00	Ready to ship
25mg	USD 250.00	Ready to ship
50mg	USD 450.00	Ready to ship
100mg	USD 750.00	Ready to ship
200mg	USD 1,350.00	Ready to ship
500mg	USD 2,850.00	Ready to ship

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

4E1RCat; eIF4E/eIF4G Interaction Inhibitor II.

IUPAC/Chemical Name

(Z)-4-(3-((5-(4-nitrophenyl)furan-2-yl)methylene)-2-oxo-5-phenyl-2,3-dihydro-1H-pyrrol-1-yl)benzoic acid

InChi Key

BBQRBOIMSKMFFO-PGMHBOJBSA-N

InChi Code

InChI=1S/C28H18N2O6/c31-27-21(16-24-14-15-26(36-24)19-6-12-23(13-7-19)30(34)35)17-25(18-4-2-1-3-5-18)29(27)22-10-8-20(9-11-22)28(32)33/h1-17H,(H,32,33)/b21-16-

SMILES Code

O=C1/C(C=C(C2=CC=CC=C2)N1C3=CC=C(C(O)=O)C=C3)=C\C4=CC=C(C5=CC=C([N+]([O-])=O)C=C5)O4

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Certificate of Analysis

View CoA: current batch, Lot# A9T03K04

QC Data

View QC data: current batch, Lot# A9T03K04

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Biological target:

4E1RCat is an inhibitor of cap-dependent translation, and inhibits eIF4E:eIF4GI interaction, with an IC50 an of ∼4 μM.

In vitro activity:

Twenty-six hours posttransfection cells were treated with 4E1RCat, a known chemical inhibitor of eIF4F complex. 4E1RCat binds to eIF4E, disrupts the interactions between eIF4E and eIF4G, and prevents the formation of eIF4F complex on the mRNA 5’ cap. As a result, the cap-dependent translation machinery of the host cell is shut down. The microscopic examination of cells 24 h after 4E1RCat treatment revealed that translational shutdown inhibited the translation of GFP and mCherry reporter mRNAs in cells (Fig. 7ii and v). The treatment of 4E1RCat failed to inhibit the translation of mCherry reporter mRNA in SNV N protein-expressing cells (Fig. 7vi and viii), further confirming the previously reported observations that N protein does not require eIF4F complex to facilitate mRNA translation. Reference: J Virol. 2017 Aug 1; 91(15): e00636-17. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5512247/

In vivo activity:

The combination of 1 mg/kg Sal and 10 mg/kg 4E1RCat was found to impair tumor growth greatest after 20 days (Figure 2A), and was thus chosen for further investigation. Similar results in the UACC 903 and 1,205 Lu cell lines confirmed that the observed results were not specific to a particular cell line and that the 1:10 mg/kg combination significantly impaired xenograft tumor growth greater than either drug alone (Figures 2B,C). Furthermore, it did not significantly alter mouse body weight, which suggested negligible toxicity (Figures 2B,C, insets). Measurement of serum parameters from mice treated with 1 mg/kg Sal and 15 mg/kg 4E1RCat identified that levels of CAL and total protein (TP) were slightly below DMSO control levels, outside of the normal range (Table 1), which was expected since protein production was targeted. Reference: Front Oncol. 2020 Jun 19;10:834. https://pubmed.ncbi.nlm.nih.gov/32637352/

	Solvent	mg/mL	mM
Solubility
	DMSO	37.1	77.46
	DMF	5.0	10.45

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 478.46 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Jeeva S, Cheng E, Ganaie SS, Mir MA. Crimean-Congo Hemorrhagic Fever Virus Nucleocapsid Protein Augments mRNA Translation. J Virol. 2017 Jul 12;91(15):e00636-17. doi: 10.1128/JVI.00636-17. PMID: 28515298; PMCID: PMC5512247. 2. Kardos GR, Gowda R, Dinavahi SS, Kimball S, Robertson GP. Salubrinal in Combination With 4E1RCat Synergistically Impairs Melanoma Development by Disrupting the Protein Synthetic Machinery. Front Oncol. 2020 Jun 19;10:834. doi: 10.3389/fonc.2020.00834. PMID: 32637352; PMCID: PMC7317660.

In vitro protocol:

In vivo protocol:

1. Kardos GR, Gowda R, Dinavahi SS, Kimball S, Robertson GP. Salubrinal in Combination With 4E1RCat Synergistically Impairs Melanoma Development by Disrupting the Protein Synthetic Machinery. Front Oncol. 2020 Jun 19;10:834. doi: 10.3389/fonc.2020.00834. PMID: 32637352; PMCID: PMC7317660.

1: Shuda M, Velásquez C, Cheng E, Cordek DG, Kwun HJ, Chang Y, Moore PS. CDK1 substitutes for mTOR kinase to activate mitotic cap-dependent protein translation. Proc Natl Acad Sci U S A. 2015 May 12;112(19):5875-82. doi: 10.1073/pnas.1505787112. PubMed PMID: 25883264; PubMed Central PMCID: PMC4434708. 2: Arnold N, Koppula PR, Gul R, Luck C, Pulakat L. Regulation of cardiac expression of the diabetic marker microRNA miR-29. PLoS One. 2014 Jul 25;9(7):e103284. doi: 10.1371/journal.pone.0103284. PubMed PMID: 25062042; PubMed Central PMCID: PMC4111545.